Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients

American Journal of Physiology - Endocrinology and Metabolism

Volumn 297, Issue 1, 2009, Pages

  Gastaldelli, Amalia ^a   Casolaro, Arturo ^a   Ciociaro, Demetrio ^a   Frascerra, Silvia ^a   Nannipieri, Monica ^a   Buzzigoli, Emma ^a   Ferrannini, Ele ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Dyslipidemia; Insulin resistance; Thiazolidinediones; Type 2 diabetes

Indexed keywords

3 HYDROXYBUTYRIC ACID; ANTILIPEMIC AGENT; FATTY ACID; GLYCEROL; INSULIN; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; FEMALE; GLYCEROL BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPOLYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; GLYCEROL; HUMANS; INSULIN; LIPOLYSIS; MALE; MIDDLE AGED; PLACEBOS; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 67650093467     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.90960.2008     Document Type: Article

References (32)

1. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Hakkinen A, Olofsson SO, Yki-Jarvinen H, Boren J. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49: 755-765, 2006.
2. Al Majali K, Cooper MB, Staels B, Luc G, Taskinen MR, Betteridge DJ. The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia 49: 527-537, 2006.
3. Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, Spila-Alegiani S, Turco S, Velussi M, Ferrannini E. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 30: 1241-1247, 2007.
4. Basu R, Shah P, Basu A, Norby B, Dicke B, Chandramouli V, Cohen O, Landau BR, Rizza RA. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes. Diabetes 57: 24-31, 2008.
5. Betteridge DJ. Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab 9: 640-647, 2007.
6. Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 27: 1660-1667, 2004.
7. Cadoudal T, Blouin JM, Collinet M, Fouque F, Tan GD, Loizon E, Beale EG, Frayn KN, Karpe F, Vidal H, Benelli C, Forest C. Acute and selective regulation of glyceroneogenesis and cytosolic phosphoenolpyruvate carboxykinase in adipose tissue by thiazolidinediones in type 2 diabetes. Diabetologia 50: 666-675, 2007.
8. Castro Cabezas M, de Bruin TW, de Valk HW, Shoulders CC, Jansen H, Willem Erkelens D. Impaired fatty acid metabolism in familial combined hyperlipidemia A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest 92: 160-168, 1993.
9. Felber JP, Ferrannini E, Golay A, Meyer HU, Theibaud D, Curchod B, Maeder E, Jequier E, DeFronzo RA. Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. Diabetes 36: 1341-1350, 1987.
10. Gastaldelli A, Casolaro A, Pettiti M, Nannipieri M, Ciociaro D, Frascerra S, Buzzigoli E, Baldi S, Mari A, Ferrannini E. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes. Clin Pharmacol Ther 81: 205-212, 2007.
11. Gastaldelli A, Coggan AR, Wolfe RR. Assessment of methods for improving tracer estimation of non-steady-state rate of appearance. J Appl Physiol 87: 1813-1822, 1999.
12. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA. Glucose and free fatty acid metabolism in non-insulin- dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 84: 205-213, 1989.
13. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 8: 1122-1128, 2002.
14. Jensen MD. Regional glycerol and free fatty acid metabolism before and after meal ingestion. Am J Physiol Endocrinol Metab 276: E863-E869, 1999.
15. Kelley D, Mandarino L. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 49: 677-683, 2000.
16. Kelley DE, Williams KV, Price JC, McKolanis TM, Goodpaster BH, Thaete FL. Plasma fatty acids, adiposity, and variance of skeletal muscle insulin resistance in type 2 diabetes mellitus. J Clin Endocrinol Metab 86: 5412-5419, 2001.
17. Koska J, Ortega E, Bogardus C, Krakoff J, Bunt JC. The effect of insulin on net lipid oxidation predicts worsening of insulin resistance and development of type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 293: E264-E269, 2007.
18. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51: 797-802, 2002.
19. Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A, Fruchart-Najib J, Holleran S, Cohn JS, Ramakrishnan R, Ginsberg HN. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 115: 1323-1332, 2005.
20. Oakes ND, Thalen PG, Jacinto SM, Ljung B. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 50: 1158-1165, 2001.
21. Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 12: 1336-1345, 1992.
22. Qin S, Liu T, Kamanna VS, Kashyap ML. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha. Arterioscler Thromb Vasc Biol 27: 2428-2434, 2007.
23. Swislocki AL, Chen YD, Golay A, Chang MO, Reaven GM. Insulin suppression of plasma-free fatty acid concentration in normal individuals and patients with type 2 (non-insulin-dependent) diabetes. Diabetologia 30: 622-626, 1987.
24. Tan GD, Debard C, Tiraby C, Humphreys SM, Frayn KN, Langin D, Vidal H, Karpe F. A "futile cycle" induced by thiazolidinediones in human adipose tissue? Nat Med 9: 811-812, 2003.
25. Tan GD, Fielding BA, Currie JM, Humphreys SM, Desage M, Frayn KN, Laville M, Vidal H, Karpe F. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48: 83-95, 2005.
26. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46: 733-749, 2003.
27. van Wijk JP, Halkes CJ, Erkelens DW, Castro Cabezas M. Fasting and daylong triglycerides in obesity with and without type 2 diabetes. Metabolism 52: 1043-1049, 2003.
28. van Wijk JPH, de Koning EJP, Castro Cabezas M, Rabelink TJ. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care 28: 844-849, 2005.
29. Viljanen AP, Virtanen KA, Jarvisalo MJ, Hallsten K, Parkkola R, Ronnemaa T, Lonnqvist F, Iozzo P, Ferrannini E, Nuutila P. Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin. J Clin Endocrinol Metab 90: 6523-6528, 2005.
30. Virtanen KA, Iozzo P, Hallsten K, Huupponen R, Parkkola R, Janatuinen T, Lonnqvist F, Viljanen T, Ronnemaa T, Lonnroth P, Knuuti J, Ferrannini E, Nuutila P. Increased fat mass compensates for insulin resistance in abdominal obesity and type 2 diabetes: a positron-emitting tomography study. Diabetes 54: 2720-2726, 2005.
31. Wolfe R. Radioactive and Stable Isotope Tracers in Biomedicine. New York: Wiley-Liss, 1992.
32. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351: 1106-1118, 2004.